A Global Trial, Focused on Women

WARRIORS is an international randomized controlled trial enrolling women across centers in North America, Europe, and Australasia. A total of 1,112 women are planned to participate worldwide, with 350 enrolled at U.S. sites.

This is the first large-scale clinical trial designed exclusively to address the evidence gap in AAA management for women. Its findings have the potential to change clinical guidelines and improve care for women globally.

Trial Leadership & Structure

The trial is governed by an International Clinical Trial Coordinating Center hosted by Imperial College London. Within the United States, the trial is managed by a U.S. Trial Management Group:

  • Clinical Coordinating Center: Stanford University — Principal Investigator: Dr. Shipra Arya
  • Data Coordinating Center: University of Alabama at Birmingham (UAB) — Principal Investigators: Dr. Jeff Szychowski, Dr. Adam Beck
  • S. Funding: National Institute of Health: National Heart, Lung, and Blood Institute (NIH-NHLBI)
  • National Data Registry Partner: Society for Vascular Surgery (SVS) Vascular Quality Initiative (VQI)

[EDITOR NOTE: Insert trial structure diagram here (Imperial UK Steering Committee → US Trial Management Group [Stanford CCC + UAB DCC] → Individual WARRIORS Study Sites + SVS VQI). Image provided in investigators’ PDF.]

The Role of VQI

All U.S. participating sites are members of the Society for Vascular Surgery (SVS) Vascular Quality Initiative (VQI) — a national registry through which vascular surgery programs already collect standardized data on patient outcomes. By conducting WARRIORS through VQI-affiliated sites, the trial leverages existing infrastructure in the EVAR and vascular medicine registries to collect data at treatment and at one- and five-year follow-ups. Many of these sites have a strong track record of performing aneurysm repairs in women.

How Follow-Up Works

WARRIORS uses a centralized follow-up model. Participating sites enroll women during an active enrollment phase of approximately 18–24 months. Once enrollment at a site is complete, the site’s active trial role concludes. All subsequent research follow-up — surveys, outcome tracking, and adverse event monitoring — will be conducted and managed centrally by Stanford and UAB.

This transition is an important feature of how the trial operates and will be explained fully during the consent process. Participants should expect to hear from the Stanford/UAB research team for their ongoing research check-ins after their site’s enrollment period ends. As a reminder, your regular medical care continues with your own provider.

U.S. Trial Sites

[EDITOR NOTE: Insert U.S. map with star pins on participating site locations (image provided in investigators’ PDF). Below the map, include a table: Study Site | City, State | Site Principal Investigator | Site PI Email. Investigators to populate site details.]

WARRIORS is enrolling women at approximately 35 sites across the United States. To find out whether a site near you is participating, contact us at warriorstrialUSA@stanford.edu or consult with your vascular surgeon.

 

[EDITOR NOTE: Consider adding Executive Team profiles with small headshots — images should be compact so they don’t dominate the page.]